AT-Patch (ATP-C130/ATP-C70) vs Impala
AI Verdict
Choose AT-Patch (ATP-C130/ATP-C70) if…
Choose AT-Patch if you require extended, continuous cardiac monitoring for up to 14 days in a patient's natural environment. Its shower-proof design and lightweight form factor ensure patient comfort and compliance, making it ideal for detecting intermittent arrhythmias that might be missed during shorter monitoring periods. The integrated AI analysis further streamlines the detection process for healthcare providers.
View AT-Patch (ATP-C130/ATP-C70) →Choose Impala if…
Choose Impala if you are a healthcare professional needing a portable, rapid, and diagnostic-quality 12-Lead ECG for immediate cardiac assessment. Its AI-powered technology and reduced leadset enable quick detection of life-threatening conditions, making it particularly well-suited for emergency medicine or situations requiring on-the-spot, comprehensive cardiac evaluation.
View Impala →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AT-Patch (ATP-C130/ATP-C70) | Impala |
|---|---|---|
| Pricing | N/a | Contact for pricing |
| Deployment | Wearable device for patients; analysis software deployed on-premise at medical institutions. | Portable device, integrated with mobile applications/platforms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AT-Patch (ATP-C130/ATP-C70)AT-Patch excels in patient-centric usability for continuous monitoring, offering a lightweight (13g), shower-proof device that requires no charging or electrode replacement for up to 14 days, enhancing patient comfort and adherence. While Impala offers simplified lead placement for healthcare professionals, AT-Patch's design directly addresses the challenges of long-term patient wear in daily life.
Clinical Value
ImpalaImpala provides a portable, AI-powered 12-Lead ECG system that acquires and synthesizes a full 12-lead recording from a reduced leadset, enabling rapid and accurate detection of 35 cardiac determinations, including acute myocardial infarction and ischemia. While AT-Patch offers valuable long-term continuous monitoring for arrhythmias, Impala's capability for immediate, gold-standard 12-lead diagnostics for acute, life-threatening conditions gives it a critical edge in clinical impact.
Pricing & Value
TieNeither AT-Patch nor Impala provides publicly available pricing information, both requiring direct contact for quotes. This lack of transparency makes it impossible to conduct a head-to-head comparison of their pricing structures or assess their relative value.
Enterprise Readiness
ImpalaImpala explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), which are crucial for healthcare organizations handling Protected Health Information. While AT-Patch is likely HIPAA compliant, Impala's clear documentation and offering of a BAA demonstrate a more robust and transparent approach to enterprise-level data security and regulatory adherence.
Innovation
ImpalaImpala showcases significant innovation by delivering a portable, AI-powered 12-lead ECG system that simplifies lead placement and reduces acquisition time, making comprehensive cardiac diagnostics more accessible for rapid assessments. While AT-Patch's long-term, maintenance-free wearable design is innovative for continuous monitoring, Impala's ability to provide a 12-lead equivalent from a reduced leadset for critical acute conditions represents a more impactful technological advancement in immediate diagnostic capabilities.
Support & Docs
TieThe provided structured facts and web searches do not offer sufficient specific information to differentiate between the two tools regarding their support services or documentation for healthcare professionals. Neither tool's entry or search results provided detailed insights into these aspects.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AT-Patch (ATP-C130/ATP-C70) | Impala |
|---|---|---|
| Product Name | AT-Patch (ATP-C130/ATP-C70) | Impala |
| Company | ATsens Co. | AliveCor |
| Monitoring Duration | Up to 14 days of continuous ECG monitoring (ATP-C130) | Not specified |
| ECG Lead Type/Acquisition | High-performance sensor chip for accurate ECG signal acquisition | Portable 12-Lead ECG acquisition; acquires 4 standard diagnostic-bandwidth leads, derives 4 standard diagnostic-bandwidth leads, and software generates remaining leads for 12-Lead recording. |
| AI Analysis | Integrated AI-powered analysis software for enhanced arrhythmia detection; AT-Report software with AI/machine learning algorithms for ECG analysis. | AI technology (KAIu2122 12L) for cardiac determinations; detects life-threatening cardiac conditions, including heart attacks. |
| Design/Form Factor | Wearable ECG monitor; shower-proof design (IP57 for ATP-C130, IP44 for ATP-C70); compact and lightweight (13g). | Portable, AI-powered 12-Lead ECG device; reduced leadset for easier placement (single cable with 5 electrodes for 8 diagnostic-quality leads). |
Videos
Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Impala.
Frequently Asked Questions
More Comparisons
More matchups featuring AT-Patch (ATP-C130/ATP-C70) or Impala
Backers
Who funded each tool's parent company.